New hope for advanced HER2 cancers? early trial of A166 underway
NCT ID NCT05311397
First seen Nov 17, 2025 · Last updated Apr 24, 2026 · Updated 18 times
Summary
This early-phase study tests a new drug called A166 in 120 adults with advanced HER2-expressing solid tumors (like breast cancer) that cannot be removed by surgery or have spread. The main goal is to check safety and find the right dose, while also seeing if tumors shrink. Participants must have already tried standard treatments without success.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
Conditions
Explore the condition pages connected to this study.